ITP: Is Rituximab Superior to Splenectomy as A Second-line Therapy?

Share this content:
Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatmen
Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatmen

Patients with steroid-refractory immune thrombocytopenic purpura (ITP) may not have significantly different responses to rituximab or splenectomy as second-line therapy, according to a study published in The International Journal of Hematology.1

ITP is a common hematologic disease whose hallmark characteristic is thrombocytopenia, and is primarily treated with corticosteroids. Previous studies have demonstrated that in patients who are refractory to primary treatment, splenectomy or rituximab have been effective as second-line therapies.

In this retrospective single-center study, researchers evaluated the outcomes of 143 patients with ITP who had no response to or were unable to wean off of corticosteroid therapy, 19 of whom received intravenous rituximab 375 mg/m2 for 4 weeks and 11 who underwent splenectomy. Platelet levels at diagnosis were not significantly different between the study arms (P = .062), and patients in the splenectomy arm were younger (P = .011). Response to treatment was measured every 3 months.

There was no significant difference between the rates of no response compared with complete response in patients receiving rituximab or splenectomy as second-line therapy (odds ratio [OR], 2.03; 95% CI, 0.21-22.90; P = .549).


No statistically significant differences in platelet counts were observed between the 2 study groups over time (P = .101).

Three patients in each study arm progressed to third-line therapy.

The authors of the study concluded that even though the response rate did not differ significantly between rituximab and splenectomy, “further large studies are needed to assess the response rate directly comparing the two treatment modalities as second-line therapy.”

Reference

  1. Al Askar AS, Shaheen NA, Al Zahrani M, et al. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience. Int J Hematol. 2017 Sep 11. doi: 10.1007/s12185-017-2325-y [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters